

MUNICH  
2018

ESMO

congress tv

# ESMO Congress TV Debuts in Munich

**WebsEdge will be producing ESMO TV in Munich, Germany at the ESMO 2018 Congress. Where scientific and educational programmes are provided to directly impact the daily clinical practice of oncologists.**

ESMO Congress TV serves as a unique platform to highlight the conference. The programmes will have session highlights, interviews with key speakers and interviews with delegates to hear their reactions to topics as well as their insights. The program will also show feature films from universities, institutions and organisations to highlight programmes, case studies and ongoing initiatives that are making a difference in the field of oncology.

## Where to find ESMO Congress TV

**Twitter:** @WebsEdge\_Health

**Facebook:** @WebsEdgeHealth


**YouTube Channel:** <https://www.youtube.com/ESMOchannel>

**YouTube Channel:** <https://www.youtube.com/WebsEdgeHealth>

**WebsEdge:** [http://www.websedge.com/videos/ESMO\\_tv\\_2018/](http://www.websedge.com/videos/ESMO_tv_2018/)

**Follow along with the ESMO 2018 Congress on twitter:**

#ESMO18 @myESMO @WebsEdge\_Health



# ESMO Congress TV Highlights



Palliative and supportive care plays an essential part in the treatment of cancer patients, with proven effects including improved survival, symptom control, reduced anxiety, depression as well as overall improved quality of life at lower



cost to healthcare providers. However due to a lack of international standards, misunderstanding about the role of palliative care as solely end-of-life care, stigma around death and dying, as well as lack of funding and infrastructure, palliative and supportive care is often poorly or incompletely implemented into the care of cancer patients. At Oslo University Hospital doctors and clinical staff have been working for the last decade to rethink the way palliative and supportive care is integrated into mainstream oncology, undertaking research to determine how best to care for patients. Through systematic assessment and the use of patient-reported outcomes, researchers are working to establish integrated care pathways, brought together by multidisciplinary teams, and implemented through improved training and education of all clinical staff. At the same time, by working with molecular biologists and other scientists conducting basic research, they are also developing a better understanding of the biological and clinical effect of living with cancer to better manage pain and quality of life during and after treatment.

**Oslo University Hospital**



Heralded nationally, Miami Cancer Institute is the new model for access to personalized cancer prevention and care, forging new ground in cancer research and discovery, pioneering local access to internationally renowned, sub-specialized expert teams, and delivering the most effective, targeted treatments and best outcomes to the local patients who need them. The region's only cancer center selected as a certified member of the Memorial Sloan Kettering Cancer Alliance, Miami Cancer Institute brings to South Florida and beyond unparalleled expertise in the prevention, detection, accurate diagnosis, treatment and survivorship of individual cancers.

**Baptist Health South Florida/Miami Cancer Institute**



HELLENIC REPUBLIC  
UNIVERSITY OF IOANNINA

The DMO-UI is based in a tertiary university general hospital in North-Western Greece and is affiliated with the Medical School, University of Ioannina. The strategic mission is to practice and promote Holistic Oncology and



European Integration. Holistic Oncology is defined by 1. Multidisciplinary, 2. Oncological care integrating supportive, palliative and psycho-oncological care, 3. Access to innovative therapies via Clinical Trials and active translational research. European integration is defined as development of research, education and clinical care links with European centers of excellence and scientific societies/research organisations. The main activities and accomplishments of DMO-UI are: 1. Multidisciplinary Oncology- tumour boards by tumour type. 2. ESMO designated centre for integrated Oncology, Palliative and

Supportive/psychosocial care. 3. Clinical Trials Unit, including phase I trials. 4. Liquid Biopsies research infrastructure: first public hospital in Greece with such infrastructure. 5. Translational research at University of Ioannina and Investigator-Initiated Academic Trials (IITs) within the Hellenic Cooperative Oncology Group (HeCOG). 6. European affiliations (ESMO, EORTC, SAKK) 7. Educational opportunities: educational program with web-based lectures, weekly visits in Phase I trial centres, international medical seminars. 8. Cooperation with Patient Advocacy Group.

**Dept. of Medical Oncology, Medical School, University of Ioannina, Greece**



The Breast Center at Geneva

University Hospital Centre of Oncology brings together, in a single location, a multidisciplinary team and a state-of-the-art technical platform. The centre contributes to ensuring the best treatment at each step of care, from diagnosis to rehabilitation. Patients can find all the support



and care they need, from a social, psychological, physiotherapeutic, nursing and medical point of view. The aim is to treat the whole patient, not just the disease, including the way to ease pain fatigue and anxiety by offering physical activities program supervised by physiotherapists and sports master. By offering hypnosis sessions in order to decrease pain, nausea, fatigue and anxiety related to treatment or cancer itself, offering a mindfulness program to relax, better control pain, stress, depression and insomnia and also having nutrition counselling in aim to manage weight changes and to give diet advice to improve health.

**Geneva University Hospital Centre of Oncology**



Gustave Roussy is the premier European Cancer Centre. It is a centre for patient care, research and teaching and patients with all types of cancer can be treated there.

It looks to place innovation at the heart of a human, scientific and technological revolution in the fight against cancer.

We deploy cutting-edge research with the aim of making major discoveries, with our doctors we are establishing more individualised and less invasive



medicine, we administer high quality treatment under the safest conditions, we are investing in the most modern technologies and we are developing innovative pathways to offer patients and their families well-being, good communication and help in these times of difficulty.

**Gustave Roussy**



LYriCAN is joint project between the Centre Léon Bérard and the Hospices

Civils de Lyon, dedicated to translational research. The ambition of the LYriCAN is to tackle tumor and immune cell plasticity involved in tumor development and progression, as well as resistance mechanisms. Expected impacts from the three integrated research programs are therapeutic innovation as well as setting up next generation clinical trials. LYriCAN projects rely on on-going and future molecular profiling trials in



order to improve tomorrow's precision medicine. Social and humanities science projects are integrated with the research programs and aim to address today's changes of organization or paradigm in oncology on medical staff, patients and civil society.

**LYriCAN (Lyon Recherche Innovation contre le Cancer)**



MARIA SKŁODOWSKA-CURIE INSTITUTE - ONCOLOGY CENTER

MSCI is a governmental research institution and leading national referral comprehensive cancer center. Established in 1932 as Radium Institute following the 1921 initiative of double Nobel Prize winner Maria Skłodowska-Curie who raised funds in the USA for the first gram of radium and envisioned the Institute combining patient care and scientific research.

The National Cancer Registry is hosted and managed by the Institute with 16 regional registries and 90% histopathologic confirmation.

MSCI is designated European Reference Network institution for rare diseases in subnetworks for solid tumors - EURACAN,



hematological diseases – EuroBloodNet, and neuroendocrine tumors - EndoERN.

MSCI is associated with a number of international collaborative research groups including European Organisation for Research and Treatment of Cancer (EORTC) hosting EORTC Liason Office. Collaboration with ESMO and ASCO has a long record.

Department of Cancer Prevention coordinates the national screening programs for colorectal, breast and cervical cancer. Leading center for large European randomized trials on colorectal cancer prevention, including the Northern-European Initiative on Colorectal Cancer (NordICC) and the European Polyp Surveillance Study (EPoS). It also provides top quality education on cancer prevention and early cancer treatment including the School of Colonoscopy and the Warsaw Live Endoscopy.

**Maria Skłodowska Curie Cancer Institute**



**National Cancer Center Japan**



The National Cancer Center of Japan, well established as a leader both in clinical practice and in research for over five decades, is welcoming partners for drug development. With abundant genomic and clinical data, biobank samples collected under the universal healthcare system in Japan, and expertise with drug approval from authorities, we can serve as your trusted gateway to Asia.

**National Cancer Center Hospital (NCCH) - Japan**



National Cancer Centre Singapore SingHealth

The National Cancer Centre Singapore is the largest

and comprehensive cancer centre in Singapore, and sees close to 65% of public sector cancer patients. Investing heavily in training, technology, safety and patient care, staff at NCCS get exposure to the very best in oncology. Using a



multi-disciplinary and holistic approach to treatment, clinicians discuss complex patient cases at tumour board meetings to decide on the best options for each case. At the same time, strong research teams comprising of scientists and clinicians working together are constantly working on new research to bring hope to patients.

**National Cancer Centre of Singapore**

**NTU CANCER CENTER**  
國立臺灣大學醫學院 癌醫中心醫院



The National Taiwan University Cancer Center provides high quality, comprehensive cancer treatment and research.

The film showcases multimodality cancer care in NTU, Cancer research including both translation research and clinical trials, including early phase, late phase and translational research in all cancer types in the NTU Hospital and the new NTU Cancer Center.

The film links the history of comprehensive cancer care in the National Taiwan University Hospital and how this extends to the new National Taiwan University Cancer Center.

**National Taiwan University Cancer Center**



Peter MacCallum Cancer Centre are a leader in the area of clinical treatment and translational research across a wide range of cancers.

**Peter Mac**  
Peter MacCallum Cancer Centre  
Victoria Australia

Housed in a brand new building in the heart of Melbourne Australia, Peter Mac is home to world-class medical



oncology clinician researchers who are making major differences in the field of oncology, and in their patients' lives. Professor Danny Rischin (Director, Department of Cancer Medicine & Head of Dept Medical Oncology) has made major breakthroughs with a clinical trial demonstrating the new immunotherapy drug cemiplimab - James Dunn, a long-time patient of

Peter Mac, has seen incredible results in his advanced skin cancer.

By combining diverse expertise in a state-of-the-art environment, Peter Mac's clinicians researchers are changing the game in medical oncology.

**Peter MacCallum Cancer Centre Medical Oncology Department**



Americans of Pacific Islander ancestry is a highly underserved minority with a significant, disparate burden of cancer. In addition, they are also highly underrepresented among cancer researchers and cancer health care professionals. The University of Guam (UOG) and the University of Hawaii Cancer Center (UHCC) have been engaged in a unique and successful partnership over the past twelve years, currently supported by a U54 grant.

The UOG/UHCC Partnership has indeed been transformational for the UOG and the Territory of



Guam as specified in UOG's Letter of Commitment, including the establishment of a Cancer Research Center at UOG and implementation of legislation markedly increasing taxes on tobacco products. At UHCC the U54 has resulted in increased cancer health disparities research in Pacific Islanders. In this U54 renewal application, our overarching goal is to establish our Partner- ship as the national and international

leader in advancing cancer health equity in Pacific Islanders. To achieve this goal we will build upon the success of the last five and a half years.

**University of Guam**



**London Health Sciences Centre**

The London Regional Cancer Program at London Health Sciences Centre is a world-class cancer care facility who has been providing the highest quality care for more than 50 years. Located in Southwestern Ontario, Canada, their catchment area is the largest in the province, made up of a population of over 2.5 million across 9 different counties spanning 70km<sup>2</sup> including both urban and rural patient populations. They have been one of the leading cancer centres in Canada in clinical trial



participation and clinical research. Their personalized medicine programs and trials, translational studies, clinical trials and population-based databases help make them one of the top sites in Canada for clinical cancer research.

At the London Regional Cancer Program, they are open to increasing their presence on the world stage by networking with investigators around the world in an effort to establish clinical and scientific collaborations.

**Western University - Division of Medical Oncology - London ON, Canada**

